IXI Insider Trading

Insider Ownership Percentage: 30.28%
Insider Buying (Last 12 Months): £33,573.30
Insider Selling (Last 12 Months): GBX 0

IXICO Insider Trading History Chart

This chart shows the insider buying and selling history at IXICO by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

IXICO Share Price & Price History

Current Price: GBX 11.58
Price Change: Price Decrease of -0.42 (-3.50%)
As of 02/14/2025 08:46 AM ET

This chart shows the closing price history over time for IXI up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

IXICO Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/4/2024Grant NashInsiderBuy260,000GBX 12£31,200
10/10/2024Mark WarneInsiderBuy26,370GBX 9£2,373.30
12/22/2022Grant NashInsiderSell200,000GBX 25£50,000
See Full Table

SEC Filings (Institutional Ownership Changes) for IXICO (LON:IXI)

55.95% of IXICO stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

IXICO logo
IXICO is a fast growing and profitable medical data analytics company, providing data management and advanced analytics to the pharmaceutical clinical trials market. Established in 2004 and listed as a public company in October 2013, IXICO has firmly established itself as a trusted partner to the global pharmaceutical industry developing new therapies for neurological conditions such as Alzheimer’s, Parkinson’s and Huntington’s disease. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience. We will focus on developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients. Our integrated technology offering encompasses every stage of clinical drug development through to post marketing surveillance and we continue to invest in infrastructure and innovation to support our ambitious growth strategy. Our competitive advantage is our dedication to address complex unmet clinical research needs by partnering and collaborating with clients and academic partners early in the drug development cycle to identify and validate promising new imaging and digital biomarkers.
Read More on IXICO

Today's Range

Now: GBX 11.58
Low: 11.52
High: 11.58

50 Day Range

MA: GBX 11.84
Low: 10.75
High: 12.50

52 Week Range

Now: GBX 11.58
Low: 6.35
High: 13

Volume

4,486 shs

Average Volume

18,669 shs

Market Capitalization

£10.73 million

P/E Ratio

N/A

Dividend Yield

1.27%

Beta

0.86

Who are the company insiders with the largest holdings of IXICO?

IXICO's top insider investors include:
  1. Grant Nash (Insider)
  2. Mark Warne (Insider)
Learn More about top insider investors at IXICO.